NASDAQ:AEMD Aethlon Medical (AEMD) Stock Price, News & Analysis $2.83 -0.10 (-3.41%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$2.97 +0.14 (+5.09%) As of 08/14/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Aethlon Medical Stock (NASDAQ:AEMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aethlon Medical alerts:Sign Up Key Stats Today's Range$2.78▼$3.0550-Day Range$2.66▼$10.1552-Week Range$2.63▼$137.00Volume36,760 shsAverage Volume50,235 shsMarket Capitalization$1.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings. The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components. Aethlon has advanced the device through human clinical trials, exploring its potential in patients with viral infections—such as hepatitis C and COVID-19—and in oncology patients where tumor‐derived exosomes contribute to immune system evasion. The company continues to refine its technology, pursue regulatory designations, and seek strategic collaborations to expand its clinical development efforts. Headquartered in San Diego, California, Aethlon Medical was established with a mission to bring innovative extracorporeal therapies to market. Under the leadership of President and Chief Executive Officer Phillip D. Borden, the company engages with regulatory agencies and research institutions across North America and internationally. Aethlon’s research and development operations are complemented by partnerships aimed at accelerating the clinical evaluation of its platform and ultimately delivering new treatment options for patients with urgent medical needs.AI Generated. May Contain Errors. Read More Aethlon Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreAEMD MarketRank™: Aethlon Medical scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAethlon Medical has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAethlon Medical has only been the subject of 1 research reports in the past 90 days.Read more about Aethlon Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aethlon Medical is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aethlon Medical is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAethlon Medical has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.92% of the float of Aethlon Medical has been sold short.Short Interest Ratio / Days to CoverAethlon Medical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aethlon Medical has recently increased by 1.40%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAethlon Medical does not currently pay a dividend.Dividend GrowthAethlon Medical does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.22 News SentimentAethlon Medical has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aethlon Medical this week, compared to 3 articles on an average week.Search Interest4 people have searched for AEMD on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows1 people have added Aethlon Medical to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aethlon Medical insiders have not sold or bought any company stock.Percentage Held by Insiders0.71% of the stock of Aethlon Medical is held by insiders.Percentage Held by Institutions1.99% of the stock of Aethlon Medical is held by institutions.Read more about Aethlon Medical's insider trading history. Receive AEMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AEMD Stock News HeadlinesAethlon Medical, Inc. (AEMD) Q1 2027 Earnings Call TranscriptAugust 13 at 8:00 PM | seekingalpha.comAethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® ProgramAugust 13 at 4:15 PM | prnewswire.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 16 at 1:00 AM | Porter & Company (Ad)Aethlon Medical (AEMD) Projected to Announce Quarterly Earnings on ThursdayAugust 12, 2026 | americanbankingnews.comAethlon Medical (NASDAQ:AEMD) Upgraded at Wall Street ZenAugust 8, 2026 | americanbankingnews.comAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026August 5, 2026 | prnewswire.comAethlon MedicalJuly 13, 2026 | fool.comAethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®July 13, 2026 | prnewswire.comSee More Headlines AEMD Stock Analysis - Frequently Asked Questions How have AEMD shares performed this year? Aethlon Medical's stock was trading at $13.85 on January 1st, 2026. Since then, AEMD stock has decreased by 79.6% and is now trading at $2.83. How were Aethlon Medical's earnings last quarter? Aethlon Medical, Inc. (NASDAQ:AEMD) posted its quarterly earnings data on Thursday, August, 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing analysts' consensus estimates of ($3.92) by $0.10. Read the conference call transcript. When did Aethlon Medical's stock split? Shares of Aethlon Medical reverse split on the morning of Thursday, October 5th 2023.The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Aethlon Medical? Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aethlon Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aethlon Medical investors own include Advanced Micro Devices (AMD), Nokia (NOK), NVIDIA (NVDA), Pfizer (PFE), Plug Power (PLUG), Organigram Global (OGI). Company Calendar Last Earnings8/13/2026Today8/16/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 AEMD's financial health is in the Red zone, according to TradeSmith. AEMD has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:AEMD CIK882291 Webwww.aethlonmedical.com Phone(858) 459-7800FaxN/AEmployees10Year Founded1998Profitability EPS (Trailing Twelve Months)($73.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-119.98% Return on Assets-95.85% Debt Debt-to-Equity RatioN/A Current Ratio3.85 Quick Ratio3.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.56 per share Price / Book0.18Miscellaneous Outstanding Shares650,000Free Float645,000Market Cap$1.84 million OptionableNo Data Beta1.41 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:AEMD) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredA Dark Day Is Coming to AmericaKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredElon admits defeatElon Musk just called Anthropic the clear leader in AI, admitting its Mythos model surpasses anything he's bui...Weiss Ratings | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aethlon Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aethlon Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
